Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Qin Ding, Shuqi Huang, Zexu Sun, Kaifeng Chen, Xin Li & Qi Pei. (2022) A Review of Population Pharmacokinetic Models of Posaconazole. Drug Design, Development and Therapy 16, pages 3691-3709.
Read now
Read now
Articles from other publishers (32)
Lu Chen, Elke H.J. Krekels, Yalin Dong, Limei Chen, Johan A. Maertens, Nicole M.A. Blijlevens, Catherijne A.J. Knibbe & Roger J. Brüggemann. (2023) Meta-pharmacokinetic analysis of posaconazole following dosing of oral suspension, delayed-release tablet, and intravenous infusion in patients vs. healthy volunteers: Impact of clinical characteristics and race. International Journal of Antimicrobial Agents 62:6, pages 106995.
Crossref
Crossref
Zoe Kane, Iek Cheng, Orlagh McGarrity, Robert Chiesa, Nigel Klein, Mario Cortina-Borja, Joseph F. Standing & Silke Gastine. (2023) Model Based Estimation of Posaconazole Tablet and Suspension Bioavailability in Hospitalized Children Using Real-World Therapeutic Drug Monitoring Data in Patients Receiving Intravenous and Oral Dosing. Antimicrobial Agents and Chemotherapy 67:7.
Crossref
Crossref
Lu Chen, Elke H. J. Krekels, Anne R. Heijnen, Catherijne A. J. Knibbe & Roger J. Brüggemann. (2023) An Integrated Population Pharmacokinetic Analysis for Posaconazole Oral Suspension, Delayed-Release Tablet, and Intravenous Infusion in Healthy Volunteers. Drugs 83:1, pages 75-86.
Crossref
Crossref
Yishuo Shu, Yinping Shi, Yilei Yang, Zhonghua Dong, Qiaoyan Yi & Haiyan Shi. (2022) Progress of triazole antifungal agent posaconazole in individualized therapy. Journal of Clinical Pharmacy and Therapeutics 47:12, pages 1966-1981.
Crossref
Crossref
Danna Lin, Lihua Yu, Dewei Shang, Lulu Huang, Li Wu, Xu Liao, Yajie Zhang, Juan Zi, Jingxin Zhang, Yinghua Zeng, Xipei Wang & Lihua Yang. (2022) Population pharmacokinetics of posaconazole in Chinese pediatric patients with acute leukaemia: Effect of food on bioavailability and dose optimization. European Journal of Pharmaceutical Sciences 178, pages 106289.
Crossref
Crossref
Shuqi Huang, Qin Ding, Nan Yang, Zexu Sun, Qian Cheng, Wei Liu, Yejun Li, Xin Chen, Cuifang Wu & Qi Pei. (2022) External evaluation of published population pharmacokinetic models of posaconazole. Frontiers in Pharmacology 13.
Crossref
Crossref
Tae Kyu Chung, Hyun A. Lee, Kyeong‐Ryoon Lee, Seong Bok Jang, Kyung‐Sang Yu & Howard Lee. (2022)
A population
PK–PD
model of
YH4808
, a novel
P‐CAB
, and intragastric
pH
that incorporated negative feedback by increased intragastric
pH
onto the systemic exposure to
YH4808
. CPT: Pharmacometrics & Systems Pharmacology 11:9, pages 1223-1233.
Crossref
Crossref
Anouk M.E. Jansen, Eline W. Muilwijk, Walter J.F.M. van der Velden, Johan A. Maertens, Robina Aerts, Angela Colbers, David Burger, Paul E. Verweij, Rob ter Heine, Nicole M.A. Blijlevens & Roger J.M. Brüggemann. (2022) Posaconazole bioavailability of the solid oral tablet is reduced during severe intestinal mucositis. Clinical Microbiology and Infection 28:7, pages 1003-1009.
Crossref
Crossref
Omar ElkayalIsabel SprietAnne UyttebroeckAnca ColitaPieter AnnaertKarel AllegaertAnne Smits, Ruth Van DaeleErwin Dreesen. (2021) A Population Pharmacokinetic Modeling and Simulation Study of Posaconazole Oral Suspension in Immunocompromised Pediatric Patients: A Short Communication. Therapeutic Drug Monitoring 43:4, pages 512-518.
Crossref
Crossref
Ruth Van Daele, Roger J Brüggemann, Erwin Dreesen, Pieter Depuydt, Bart Rijnders, Frédéric Cotton, David Fage, Matthias Gijsen, Kenny Van Zwam, Yves Debaveye, Joost Wauters & Isabel Spriet. (2021) Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation. Journal of Antimicrobial Chemotherapy 76:5, pages 1234-1241.
Crossref
Crossref
Silke Gastine, William Hope, Georg Hempel, Ruta Petraitiene, Vidmantas Petraitis, Diana Mickiene, John Bacher, Thomas J. Walsh & Andreas H. Groll. (2021) Pharmacodynamics of Posaconazole in Experimental Invasive Pulmonary Aspergillosis: Utility of Serum Galactomannan as a Dynamic Endpoint of Antifungal Efficacy. Antimicrobial Agents and Chemotherapy 65:2.
Crossref
Crossref
Lu Chen, Elke H. J. Krekels, Paul. E. Verweij, Jochem B. Buil, Catherijne A. J. Knibbe & Roger J. M. Brüggemann. (2020) Pharmacokinetics and Pharmacodynamics of Posaconazole. Drugs 80:7, pages 671-695.
Crossref
Crossref
Roeland E Wasmann, Cornelis Smit, Marieke H van Donselaar, Eric P A van Dongen, René M J Wiezer, Paul E Verweij, David M Burger, Catherijne A J Knibbe & Roger J M Brüggemann. (2020) Implications for IV posaconazole dosing in the era of obesity. Journal of Antimicrobial Chemotherapy 75:4, pages 1006-1013.
Crossref
Crossref
Alexander V. Veselov. (2020) The tablet formulation of posaconazole: clinical pharmacology and the use in patients with hematologic malignancies. Clinical Microbiology and Antimicrobial Chemotherapy 22:2, pages 96-117.
Crossref
Crossref
A. Petitcollin, C. Boglione-Kerrien, C. Tron, S. Nimubona, S. Lalanne, F. Lemaitre, E. Bellissant & M.-C. Verdier. (2017) Population Pharmacokinetics of Posaconazole Tablets and Monte Carlo Simulations To Determine whether All Patients Should Receive the Same Dose. Antimicrobial Agents and Chemotherapy 61:11.
Crossref
Crossref
Morgan Belling, Abraham S. Kanate, Alexandra Shillingburg, Xiaoxiao Lu, Sijin Wen, Nilay Shah, Michael Craig & Aaron Cumpston. (2017) Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation. Leukemia Research and Treatment 2017, pages 1-6.
Crossref
Crossref
Aaron Cumpston, Ryan Caddell, Alexandra Shillingburg, Xiaoxiao Lu, Sijin Wen, Mehdi Hamadani, Michael Craig & Abraham S. Kanate. (2015) Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies. Antimicrobial Agents and Chemotherapy 59:8, pages 4424-4428.
Crossref
Crossref
Jarrett R. Amsden. (2015) Fungal Biomarkers, Antifungal Susceptibility Testing, and Therapeutic Drug Monitoring—Practical Applications for the Clinician in a Tertiary Care Center. Current Fungal Infection Reports 9:2, pages 111-121.
Crossref
Crossref
Michael J. Dolton, Roger J. M. Brüggemann, David M. Burger & Andrew J. McLachlan. (2014) Understanding Variability in Posaconazole Exposure Using an Integrated Population Pharmacokinetic Analysis. Antimicrobial Agents and Chemotherapy 58:11, pages 6879-6885.
Crossref
Crossref
Walter K. Kraft, Peter S. Chang, Marlou L. P. S. van Iersel, Hetty Waskin, Gopal Krishna & Wendy M. Kersemaekers. (2014) Posaconazole Tablet Pharmacokinetics: Lack of Effect of Concomitant Medications Altering Gastric pH and Gastric Motility in Healthy Subjects. Antimicrobial Agents and Chemotherapy 58:7, pages 4020-4025.
Crossref
Crossref
Seyedmojtaba Seyedmousavi, Johan W. Mouton, Willem J.G. Melchers, Roger J.M. Brüggemann & Paul E. Verweij. (2014) The role of azoles in the management of azole-resistant aspergillosis: From the bench to the bedside. Drug Resistance Updates 17:3, pages 37-50.
Crossref
Crossref
P.-Y. Desplanques, R. Burlacu, V. Poinsignon, H. Boussion, I. Borget, B. Wyplosz, S. de Botton, E. Billaud, E. Chachaty, B. Gachot, F. Netzer & J.-B. Micol. (2014) Factors influencing posaconazole plasmatic concentrations in patients presenting with acute myeloid leukemia. Médecine et Maladies Infectieuses 44:4, pages 174-179.
Crossref
Crossref
Maiken C. Arendrup, Manuel Cuenca-Estrella, Cornelia Lass-Flörl & William W. Hope. (2013) Breakpoints for antifungal agents: An update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp.. Drug Resistance Updates 16:6, pages 81-95.
Crossref
Crossref
Ashley L. Ross, Douglas Slain, Aaron Cumpston, Alexander M. Bryant, Mehdi Hamadani & Michael Craig. (2012) Evaluation of an alternative posaconazole prophylaxis regimen in haematological malignancy patients receiving concomitant stress ulcer prophylaxis. International Journal of Antimicrobial Agents 40:6, pages 557-561.
Crossref
Crossref
Dominic Störzinger, Stephan Borghorst, Stefan Hofer, Cornelius J. Busch, Christoph Lichtenstern, Georg Hempel, Markus A. Weigand & Torsten Hoppe-Tichy. (2012) Plasma Concentrations of Posaconazole Administered via Nasogastric Tube in Patients in a Surgical Intensive Care Unit. Antimicrobial Agents and Chemotherapy 56:8, pages 4468-4470.
Crossref
Crossref
Gopal Krishna, Lei Ma, Monika Martinho & Edward O'Mara. (2012) Single-Dose Phase I Study To Evaluate the Pharmacokinetics of Posaconazole in New Tablet and Capsule Formulations Relative to Oral Suspension. Antimicrobial Agents and Chemotherapy 56:8, pages 4196-4201.
Crossref
Crossref
J. J. Vehreschild, C. Müller, F. Farowski, M. J. G. T. Vehreschild, O. A. Cornely, U. Fuhr, K.-A. Kreuzer, M. Hallek & V. Kohl. (2012) Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. European Journal of Clinical Pharmacology 68:6, pages 987-995.
Crossref
Crossref
Oliver A. Cornely, David Helfgott, Amelia Langston, Werner Heinz, Jörg-Janne Vehreschild, Maria J. G. T. Vehreschild, Gopal Krishna, Lei Ma, Susan Huyck & Michael C. McCarthy. (2012) Pharmacokinetics of Different Dosing Strategies of Oral Posaconazole in Patients with Compromised Gastrointestinal Function and Who Are at High Risk for Invasive Fungal Infection. Antimicrobial Agents and Chemotherapy 56:5, pages 2652-2658.
Crossref
Crossref
Susan J Howard, Timothy W Felton, Alicia Gomez-Lopez & William W Hope. (2012) Posaconazole: The Case for Therapeutic Drug Monitoring. Therapeutic Drug Monitoring 34:1, pages 72-76.
Crossref
Crossref
Russell E. Lewis. (2011) Current Concepts in Antifungal Pharmacology. Mayo Clinic Proceedings 86:8, pages 805-817.
Crossref
Crossref
Susan J. Howard, Jodi M. Lestner, Andrew Sharp, Lea Gregson, Joanne Goodwin, Joanne Slater, Jayesh B. Majithiya, Peter A. Warn & William W. Hope. (2011) Pharmacokinetics and Pharmacodynamics of Posaconazole for Invasive Pulmonary Aspergillosis: Clinical Implications for Antifungal Therapy. The Journal of Infectious Diseases 203:9, pages 1324-1332.
Crossref
Crossref
Alexander M. Bryant, Douglas Slain, Aaron Cumpston & Michael Craig. (2011) A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis. International Journal of Antimicrobial Agents 37:3, pages 266-269.
Crossref
Crossref